TY  - JOUR
AU  - Vinsensia, Maria
AU  - Chyoke, Peter L
AU  - Hadaschik, Boris
AU  - Holland-Letz, Tim
AU  - Moltz, Jan
AU  - Kopka, Klaus
AU  - Rauscher, Isabel
AU  - Mier, Walter
AU  - Schwaiger, Markus
AU  - Haberkorn, Uwe
AU  - Mauer, Tobias
AU  - Kratochwil, Clemens
AU  - Eiber, Matthias
AU  - Giesel, Frederik
TI  - 68Ga-PSMA PET/CT and Volumetric Morphology of PET-Positive Lymph Nodes Stratified by Tumor Differentiation of Prostate Cancer.
JO  - Journal of nuclear medicine
VL  - 58
IS  - 12
SN  - 2159-662X
CY  - New York, NY
PB  - Soc.
M1  - DKFZ-2017-06256
SP  - 1949 - 1955
PY  - 2017
AB  - 68Ga-prostate-specific membrane antigen (PSMA) PET/CT is a new method to detect early nodal metastases in patients with biochemical relapse of prostate cancer. In this retrospective investigation, the dimensions, volume, localization, and SUVmax of nodes identified by 68Ga-PSMA were correlated to their Gleason score (GS) at diagnosis. Methods: All PET/CT images were acquired 60 ± 10 min after intravenous injection of 68Ga-PSMA (mean dose, 176 MBq). In 147 prostate cancer patients (mean age, 68 y; range, 44-87 y) with prostate-specific antigen relapse (mean prostate-specific antigen level, 5 ng/mL; range, 0.25-294 ng/mL), 362 68Ga-PSMA PET-positive lymph nodes (LNs) were identified. These patients were classified on the basis of their histopathology at primary diagnosis into either low- (GS ≤ 6, well differentiated), intermediate- (GS = 7, moderately differentiated), or high-GS cohorts (GS ≥ 8, poorly differentiated prostate cancer). Using semiautomated LN segmentation software (Fraunhofer MEVIS), we measured node volume and short-axis dimensions (SADs) and long-axis dimensions based on CT and compared with the SUVmax Nodes demonstrating uptake of 68Ga-PSMA with an SUVmax of 2.0 or more were considered PSMA-positive, and nodes with an SAD of 8 mm or more were considered positive by morphologic criteria. Results: Mean SUVmax was 13.5 (95
KW  - (68Ga)Glu-urea-Lys(Ahx)-HBED-CC (NLM Chemicals)
KW  - Antigens, Surface (NLM Chemicals)
KW  - Organometallic Compounds (NLM Chemicals)
KW  - Radiopharmaceuticals (NLM Chemicals)
KW  - Glutamate Carboxypeptidase II (NLM Chemicals)
KW  - glutamate carboxypeptidase II, human (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:28637799
DO  - DOI:10.2967/jnumed.116.185033
UR  - https://inrepo02.dkfz.de/record/131624
ER  -